The company said in a June statement that drugs like Remicade, used to treat conditions like ulcerative colitis, can cost roughly $30,000 annually.
“While life-saving and life-changing, this presents a significant challenge for health plans and can be financially devastating for patients,” the statement said.
Biosimilars are clinically equivalent alternatives to biologics like Remicade, and can reduce drug spending by up to $375 billion over the next decade, according to the statement.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.